Skip to main content
SpringerLink
Log in

Pharmacology of erection: Agents which initiate and terminate erection

  • Published:
Sexuality and Disability Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Krane RJ, Goldstein I, Saenz de Tejada I: Impotence. N Engl J Med 321:1648–1659, 1989.

    Article  PubMed  Google Scholar 

  2. Steers WD: Neural control of penile erection. Sem Urol 8:66–79, 1990.

    Google Scholar 

  3. Lue TF: Physiology of erection and pathophysiology of impotence.In Campbell's Urology, ed. by P.C. Walsh, A.B. Retik, T.A. Stamey, E.D. Vaughan Jr, 6th ed., W.B. Saunders Company, pp 709–728, 1992.

  4. Andersson K-E. Holmquist F: Mechanisms for contraction and relaxation of human penile smooth muscle. Int J Impotence Res 2:209–225, 1990.

    Google Scholar 

  5. Saenz de Tejada I: Mechanisms for the regulation of penile smooth muscle contractility.In World Book of Impotence, ed. by T.F. Lue, Smith-Gordon and Company Limited, London, pp 39–48, 1992.

    Google Scholar 

  6. Foreman MM, Wernicke JF: Approaches for the development of oral drug therapies for erectile dysfunction. Sem Urol 8:107–112, 1990.

    Google Scholar 

  7. Virag R: Intracavernous injection of papaverine for erectile failure. Lancet ii:938, 1982.

    Article  Google Scholar 

  8. Jünemann K-P, Alken P: Pharmacotherapy of erectile dysfunction: a review. Int J Impotence Res 1:71–93, 1989.

    Google Scholar 

  9. Gregoire A: New treatments for erectile impotence. Br J Psychiat 160:315–326, 1992.

    Google Scholar 

  10. Jünemann K-P: Pharmacotherapy of impotence: were are we going:In World Book of Impotence, ed. by T.F. Lue, Smith-Gordon and Company Limited, London, pp 181–188, 1992.

    Google Scholar 

  11. Goldstein, I: Comment on ‘Pharmacotherapy of impotence’.In World Book of Impotence, ed. by T.F. Lue, Smith-Gordon and Company Limited, London, pp 194–197, 1992.

    Google Scholar 

  12. van Driel MF, van de Wiel HBM, Weymar Schultz WCM, Mensink HJ: The history of papaverine in erectile dysfunction. Int J Impotence Res 4:59–63, 1992.

    Google Scholar 

  13. Ferrari M: Effects of papaverine on smooth muscle and their mechanisms. Pharmacol Res Commun 6:97–115, 1974.

    Article  PubMed  Google Scholar 

  14. Virag R, Shoukry K, Floresco J, Nollet F, Greco E: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 145: 287–293, 1991.

    PubMed  Google Scholar 

  15. Pöch G, Kukovetz WR: Papaverine-induced inhibition of phosphodiesterase activity in various mammalian tissues. Life Sci 10:133–144, 1971.

    Article  Google Scholar 

  16. Brading AF, Burdygat THV, Scipnyuk ZD: The effects of papaverine on the electrical and mechanical activity of the guinea-pig ureter. J Physiol (Lond) 334:79–89, 1983.

    Google Scholar 

  17. Huddart H, Langton PD, Saad KHM: Inhibition of papaverine of calcium movements and tension in the smooth muscle of rat vas deferens and urinary bladder. J Physiol 349:189–194, 1984.

    Google Scholar 

  18. Sunagane N, Ogawa T, Uruno T, Kubota K: Mechanism of relaxant action of papaverine. VI. Sodium ion dependence of its effects on 45Ca-efflux in guinea-pig taenia coli. Jpn J Pharmacol 38:133–139, 1985.

    PubMed  Google Scholar 

  19. Krall JF, Fittingoff M, Rajfer J: Characterization of cyclic nucleotide and inositol 1,4,5-trisphosphate-sensitive calcium-exchange activity of smooth muscle cells cultured from the human corpora cavernosa. Biol Reprod 39:913–922, 1988.

    Article  PubMed  Google Scholar 

  20. Wang Q, Large WA. Modulation of noradrenaline-induced membrane currents by papaverine in rabbit vascular smooth muscle cells. J Physiol (Lond) 439:501–512, 1991.

    Google Scholar 

  21. Kirkeby H-J, Forman A, Andersson K-E: Comparison of the papaverine effects on isolated human penile circumflex veins and corpus cavernosum. Int J Impotence Res 2:49–54, 1990.

    Google Scholar 

  22. Jünemann K-P, Lue TF, Fournier Jr GR, Tanagho EA: Hemodynamics of papaverine- and phentolamine-induced penile erection. J Urol 136:158–161, 1986.

    Google Scholar 

  23. Delcour C, Wespes E, Vandenbosch G, Schulman CC, Struyven J: The effect of papaverine on arterial and venous hemodynamics of erection. J Urol 138:187–189, 1987.

    PubMed  Google Scholar 

  24. Diederichs W, Stief CG, Lue TF, Tanagho EA: Sympathetic inhibition of papaverine induced erection. J Urol 146:195–198, 1991.

    PubMed  Google Scholar 

  25. Kim SC, Oh MM: Norepinephrine involvement in response to intracorporeal injection of papaverine in psychogenic impotence. J Urol 147:1530–1532, 1992.

    PubMed  Google Scholar 

  26. Hashmat AI, Abrahams J, Fani K, Nostrand I: A lethal complication of papaverine-induced priapism. J Urol 145:146–147, 1991.

    PubMed  Google Scholar 

  27. Seidmon EJ, Samaha Jr AM: The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacological erection. J Urol 141:1458–1459, 1989.

    PubMed  Google Scholar 

  28. Stackl W: Comment on ‘Pharmacotherapy of impotence’,In World Book of Impotence, ed. by T.F. Lue, Smith-Gordon and Company Limited, London, p 189, 1992.

    Google Scholar 

  29. Lomas GM, Jarow JP: Risk factors for papaverine-induced priapism. J Urol 147: 1280–1281. 1992.

    PubMed  Google Scholar 

  30. Hakenberg O, Wetterauer U, Koppermann U, Lühmann R: Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impotence Res 2(Supplement 2): 247–248, 1990.

    Google Scholar 

  31. Tanaka T: Papaverine hydrochloride in peripheral blood and the degree of penile erection. J Urol 143:1135–1137, 1990.

    PubMed  Google Scholar 

  32. Hedlund H, Andersson K-E: Comparison of the responses to drugs acting on adrenoceptors and muscarinic receptors in human isolated corpus cavernosum and cavernous artery. J Auton Pharmacol 5:81–88, 1985a.

    PubMed  Google Scholar 

  33. Kimura K, Kawanishi Y, Tamura M, Imagawa A: Assessment of the alpha-adrenergic receptors in isolated human and canine corpus cavernosum tissue. Int J Impotence Res 1:185–189, 1989.

    Google Scholar 

  34. Saenz de Tejada I, Kim N, Lagan I, Krane RJ, Goldstein I: Regulation of adrenergic activity in penile corpus cavernosum. J Urol 142:1117–1121, 1989b.

    PubMed  Google Scholar 

  35. Christ GJ, Maayani S, Valcic M, Melman A: Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in α-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 101:375–381, 1990.

    PubMed  Google Scholar 

  36. Kirkeby HJ, Forman A, Sørensen S, Andersson K-E: Alpha-adrenoceptor function in isolated penile circumflex veins from potent and impotent men. J Urol 142:1369–1371, 1989.

    PubMed  Google Scholar 

  37. Fontaine J, Schulman CC, Wespes E: Postjunctional alpha-1 and alpha-2-like activity in human isolated deep dorsal vein of the penis. Br J Pharmacol 89:493, 1987.

    Google Scholar 

  38. Brindley GS: Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiat 143:332–447, 1983.

    Google Scholar 

  39. Brindley GS: Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 87:495–500, 1986.

    PubMed  Google Scholar 

  40. Blum MD, Bahnson RR, Porter TN, Carter MF: Effect of local alpha-adrenergic blockade on human penile erection. J Urol 134:479–481, 1985.

    PubMed  Google Scholar 

  41. Buvat J, Lemaire A, Buvat-Herbaut M, Marcolin G: Safety of intracavernous injections using an alpha-blocking agent. J Urol 141:1364–1367, 1989.

    PubMed  Google Scholar 

  42. Brindley GS: A new treatment for priapism. Lancet ii:220–221, 1984.

    Article  Google Scholar 

  43. de Meyer JM, De Sy WA: Intracavernous injection of noradrenaline to interrupt erections during surgical interventions. Eur Urol 12:169–170, 1986.

    PubMed  Google Scholar 

  44. Taylor S, Sutherland G, MacKenzie GJ, Staunton HP, Donald KW: The circulatory effect of intravenous phentolamine. Circulation 31:741–754, 1965.

    PubMed  Google Scholar 

  45. Wespes E, Rondeux C, Schulman CC: Effect of phentolamine on venous return in human erection. Br J Urol 63:95–97, 1989.

    PubMed  Google Scholar 

  46. Imhof PR, Garnier B, Brunner L, Keller G, Rihrer T: Human pharmacology of orally administered phentolamine.In Phentolamine in Heart Failure and Other Cardiac Disorders. Proceedings of an International Workshop. London, November 1975. Ed SH Taylor, LA Gould, Hans Huber Publishers 1975, pp 11–22.

  47. Zorgniotti AW, Lefleur RS: Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 133:39–41, 1985.

    PubMed  Google Scholar 

  48. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 147:1277–1279, 1992.

    PubMed  Google Scholar 

  49. Gwinup G: Oral phentolamine in non-specific erectile insufficiency. Ann Intern Med 109: 162–163, 1988.

    PubMed  Google Scholar 

  50. ZorgniottiAW: “On demand” erection with oral preparations for impotence: 3-(N-(2-imidazoline-2ylmethyl)-p-toluidinol) phenol mesylate. Int J Impotence Res 4(Supplement 2): A99, 1992.

    Google Scholar 

  51. Stackl W, Loupal G, Holzmann A: Intracavernous injection of vasoactive drugs in the rabbit. Urol Res 16:455–458, 1988.

    Article  PubMed  Google Scholar 

  52. Flind AC: Cavernosal alpha-blockade: a warning. Br J Psychiatr 144:329–330, 1984.

    Google Scholar 

  53. Imagawa A, Kimura K, Kawanishi Y, Tamura M: Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue. Life Sci 44:619–623, 1989.

    Article  PubMed  Google Scholar 

  54. Buvat J, Buvat-Herbaut M, Lemaire A, Marcolin G: Reduced rate of fibrotic nodules in the cavernous bodies following auto-intracavernous injections of moxisylyte compared to papaverine. Int J Impotence Res. 3:123–128, 1991.

    Google Scholar 

  55. Georgotas A, Forsell TL, Mann JJ, Kim M, Gershon S: Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 2:255–267, 1982.

    PubMed  Google Scholar 

  56. Berendsen HHG, Jenck F, Broekkamp CLE. Involvement of 5-HT1C-receptors in drug-induced penile erection in rats. Psychopharmacol 101:57–61, 1990.

    Article  Google Scholar 

  57. Steers WD, de Groat WC: Effects of m-clorophenylpiperazine on penile and bladder function in rats. Am J Physiol 257:R1441-R1449, 1989.

    PubMed  Google Scholar 

  58. Blanco R, Azadzoi KM: Characterization of trazodone-associated priapism. J Urol 136:203A, 1987.

    Google Scholar 

  59. Saenz de Tejada I, Ware JC, Blanco R, Pittard JT, Nadig PW, Azadzoi KM, Krane RJ, Goldstein I: Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 145:60–64, 1991.

    PubMed  Google Scholar 

  60. Lal S, Rios O, ThavundayilJX: Treatment of impotence with trazodone: a case report. J Urol 143:819–820, 1990.

    PubMed  Google Scholar 

  61. Azadzoi KM, Payton T, Krane RJ, Goldstein I: Effects of intracavernosal trazodone hydrochloride: animal and human studies. J Urol 144:1277–1282, 1990.

    PubMed  Google Scholar 

  62. Sikora R, Sohn M, Bosshardt R, Jakse G: Trazodone in diagnosis and therapy of erectile dysfunction: preliminary results. Int J Impotence Res 4(Supplement2):A100, 1992.

    Google Scholar 

  63. Roy AC, Tan SM, Kottegoda SR, Ratnam SS: Ability of human corpora cavernosa muscle to generate prostaglandins and thromboxanes in vitro. IRCS Med Sci 12:608–609, 1984.

    Google Scholar 

  64. Bornman MS, Franz RC, Jacobs DJ, Du Plessis DJ: Thromboxane B2 production during erection. Andrologia 18:220–223, 1986.

    Article  PubMed  Google Scholar 

  65. Jeremy JY, Morgan RJ, Mikhailidis DP, Dandona P: Prostacyclin synthesis by the corpora cavernosa of the human penis: evidence for muscarinic control and pathological implications. Prostagl Leukotr Med 23:211–216, 1986.

    Article  Google Scholar 

  66. Roy AC, Adaikan PG, Sen DK, Ratnam SS: Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection. Br J Urol 64:180–182, 1989.

    PubMed  Google Scholar 

  67. Hedlund H, Andersson K-E: Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 134:1245–1250, 1985c.

    PubMed  Google Scholar 

  68. Hedlund H, Andersson K-E, Fovaeus M, Holmquist F, Uski T: Characterization of contraction-mediating prostanoid receptors in human penile erectile tissues. J Urol 141:182–186, 1989a.

    PubMed  Google Scholar 

  69. Hedlund H, Andersson K-E, Holmquist F, Uski T: Effect of thromboxane receptor antagonist AH 23848 on human isolated corpus cavernosum. Int J Impotence Res 1:19–25, 1989b.

    Google Scholar 

  70. Molderings, GJ, van Ahlen H, Göthert M: Modulation of noradrenaline release in human corpus cavernosum by presynaptic prostaglandin receptors. Int J Impotence Res 4:19–26, 1992.

    Google Scholar 

  71. Gloub M, Zia P, Mastsuno M: Metabolism of prostaglandins A and E1 in man. J Clin Invest 56:1404–1410, 1975.

    Google Scholar 

  72. Ishii N, Watanabe H, Irisawa M: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 141:323–325, 1986.

    Google Scholar 

  73. Chen J-K, Hwang TIS, Yang C-R: Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1. Br J Urol 69:404–407, 1992.

    PubMed  Google Scholar 

  74. Porst H: Prostaglandin E1 in male impotence—its diagnostic and therapeutic use in 2000 patients. Int J Impotence Res 4(Supplement)2:A88, 1992.

    Google Scholar 

  75. Fahrenkrug, J: VIP and autonomic neurotransmission. Pharmacol Ther 41:515–534 1989.

    Article  PubMed  Google Scholar 

  76. Willis E, Ottesen B, Wagner G, Sundler F, Fahrenkrug J: Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection. Acta Physiol Scand 113: 545–547, 1981.

    Article  PubMed  Google Scholar 

  77. Hedlund H, Andersson K-E: Effects of some peptides on isolated human penile erectile tissue and cavernous artery. Acta Physiol Scand 124:413–419, 1985b.

    PubMed  Google Scholar 

  78. Steers WD, McConnell J, Benson GS: Anatomical localization and some pharmacological effects of vasoactive intestinal polypeptide in human and monkey corpus cavernosum. J Urol 132:1048–1093, 1984.

    PubMed  Google Scholar 

  79. Kirkeby HJ, Fahrenkrug J, Holmquist F, Ottesen B: Vasoactive intestinal polypeptide (VIP) and peptide histidine methionine (PHM) in human penile corpus cavernosum tissue and circumflex veins: localization and in vitro effects. Eur J Clin Invest 22:24–30, 1992.

    PubMed  Google Scholar 

  80. Adaikan PG, Kottegoda SR, Ratnam SS: Is vasoactive intestinal polypeptide the principal transmitter involved in human penile erection? J Urol 135:638–640, 1986.

    PubMed  Google Scholar 

  81. Jünemann K-P, Lue TF, Huo J-A, Jadallah SI, Tanagho EA: The role of vasoactive intestinal polypeptide as a neuro-transmitter in canine penile erection: a combined in vivo and immunohistochemical study. J Urol 138:871–877, 1987.

    Google Scholar 

  82. Ottesen B, Wagner G, Virag R, Fahrenkrug J: Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br Med J 288:9–11, 1984.

    Google Scholar 

  83. Kiely EA, Blank MA, Bloom SR, Williams G: Studies on intracavernosal VIP levels during pharmacologically induced penile erections. Br J Urol 59:334–339, 1987.

    PubMed  Google Scholar 

  84. Gu J, Polak JM, Lazarides M, Morgan R, Pryor JP, Marangos PJ, Blank MA, Bloom SR: Decrease of vasoactive intestinal polypeptide (VIP) in the penises from impotent men. Lancet, ii:315–318, 1984.

    Article  Google Scholar 

  85. Jünemann K-P, Lue Luo J-A, Jadallah SA, Nunes LL, Tanagho EA: The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erection: a combined in vivo and immunohistochemical study. J Urol 138:871–873, 1987.

    Google Scholar 

  86. Aoki H, Matsuzaka J, Yeh KH, Banya Y, Fuzioka T, Kubo T, Yasuda N: Studies on the role of VIP (vasoactive intestinal polypeptide) in penile erectile function. Int J Impotence Res 2(Supplement 2):28–29, 1990.

    Google Scholar 

  87. Kiely EA, Bloom SR, Williams G: Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 64:191–194, 1989.

    PubMed  Google Scholar 

  88. Roy JB, Petrone RL, Said S: A clinical trial of intracavernous vasoactive intestinal peptide to induced penile erection. J Urol 143:302–304, 1990.

    PubMed  Google Scholar 

  89. Wagner G, Gerstenberg T: Vasoactive intestinal peptide facilitates normal erection.In Proceedings of the Sixth Biennial International Synmposium for Corpus Cavernosum Revascularization and the Third Biennial World Meeting on Impotence. Boston, Massachusetts, October 6–9, p 146, 1988.

  90. Palmer JBD, Cuss FM, Warren JB, Blank M, Bloom SR, Barnes PJ: Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax 41:663–666, 1986.

    PubMed  Google Scholar 

  91. Krejs GJ: Effect of vasoactive intestinal peptide in man. Ann N Y Acad Sci 527:501–507, 1988.

    Article  PubMed  Google Scholar 

  92. Stief CG, Benard F, Bosch RJLH, Aboseif SR, Lue T, Tanagho E: A possible role for calcitonin-gene-related peptide in the regulation of the smooth muscle tone of the bladder and penis. J Urol 143:392–397, 1990.

    PubMed  Google Scholar 

  93. Ishida-Yamamoto A, Tohyama M: Calcitonin gene-related peptide in the nervous tissue. Prog Neurobiol 33:335–386, 1989.

    Article  PubMed  Google Scholar 

  94. Hughes A. Thom S, Martin G, Sever P: Endothelial dependent relaxation of human arteries by peptide hormones. Clin Sci Suppl 13:88P, 1985.

    Google Scholar 

  95. Crossman D, McEwan J, MacDermot J, MacIntyre I, Dollery CT: Human calcitonin gene-related peptide activates adenylate cyclase and releases prostacyclin from human umbilical vein endothelial cells. Br J Pharmacol 92:695–701, 1987.

    PubMed  Google Scholar 

  96. Persson K, Garcia-Pascual A, Andersson K-E: Differences in the actions of calcitonin gene-related peptide (CGRP) in pig detrusor and vesical arterial smooth muscle. Acta Physiol Scand, 143:45–53, 1991.

    PubMed  Google Scholar 

  97. Alaranta S, Uusitalo H, Hautamäki AM, Klinge E: Calcitonin gene-related peptide: immunohistochemical localization in, and effects on, the bovine penile artery. Int J Importance Res 3:49–59, 1991.

    Google Scholar 

  98. Stief CG, Wetterauer U, Schaebsdau F, Jonas U: Calcitonin-gene-related peptide: A possible role in human penile erection and its therapeutical application in impotent patients. J Urol 146:1010, 1991b.

    PubMed  Google Scholar 

  99. Furchgott RF, Zawadski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373–376, 1980.

    Article  PubMed  Google Scholar 

  100. Furchgott RF: The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 24:175–197, 1984.

    Article  PubMed  Google Scholar 

  101. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526, 1987.

    Article  PubMed  Google Scholar 

  102. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84:9265–9269, 1987.

    Article  PubMed  Google Scholar 

  103. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen MD: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N J Engl Med 320:1025–1030, 1989a.

    Article  Google Scholar 

  104. Kimoto Y, Kessler R, Constantinou CE: Endothelium dependent relaxation of human corpus cavernosum by bradykinin. J Urol 144:1015–1017, 1990.

    PubMed  Google Scholar 

  105. Holmquist F, Andersson K-E, Hedlund H: NG-nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol Scand 141:441–442, 1991a.

    PubMed  Google Scholar 

  106. Holmquist F, Andersson K-E, Hedlund H: Characterization of inhibitory neurotransmission in the isolated corpus cavernosum from rabbit and man. J. Physiol. (Lond.) 449:295–311, 1992.

    Google Scholar 

  107. Kim N, Azadzoi KM, Goldstein I, Saenz de Tejada I: A nitric oxide-like factor mediated nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle.J Clin Invest 88:112–118, 1991.

    Article  PubMed  Google Scholar 

  108. Pickard RS, Powell PH, Zar MA: The effect of inhibitors of nitric oxide biosynthesis and cyclic GMP formation on nerve-evoked relaxation of human cavernosal smooth muscle. Br J Pharmacol 104:755–759, 1991.

    PubMed  Google Scholar 

  109. Knispel HH, Goessl C, Beckmann R: Nitric oxide mediates relaxation in rabbit and human corpus cavernosum smooth muscle. Urol Res 20:253–257, 1992.

    Article  PubMed  Google Scholar 

  110. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum on response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326:90–94, 1992.

    Article  PubMed  Google Scholar 

  111. Bush PA, Aronson WJ, Buga GM, Rajfer J, Ignarro LJ: Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 147:1650–1655, 1992.

    PubMed  Google Scholar 

  112. Holmquist, F, Stief CG, Jonas U, Andersson K-E: Effects of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. 143:299–304, 1991b.

    PubMed  Google Scholar 

  113. Burnett AL, Lowenstein CJ, Bredt DS, Chang TSK, Snyder SH: Nitric oxide: a physiologic mediator of penile erection. Science 257:401–403, 1992.

    Article  PubMed  Google Scholar 

  114. Feelisch M: Cellular and non-cellular metabolism of organic nitrates to nitric oxide: involvement of enzymic and non-enzymic pathways. In The Biology of Nitric Oxide. I Physiological and Clinical Aspects. S Moncada, MA Marletta, JB Hibbs Jr, EA Higgs (eds). Portland Press Proceedings, pp 13–17, 1992.

  115. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142, 1991.

    PubMed  Google Scholar 

  116. Reden J: Molsidomine. Blood Vessels 27:282–294, 1990.

    PubMed  Google Scholar 

  117. Wildgrube HJ, Ostrowski J, Chamberlain J, Gärtner W, Stockhausen H: Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers. Arzneim Forsch (Drug Res) 36:1129–1133, 1986.

    Google Scholar 

  118. Stief CG, Holmquist F, Allhoff EP, Andersson K-E, Jonas U: Preliminary report on the effect of the nitric oxide (NO) donor SIN-1 on human cavernous tissue in vivo. World J Urol 9: 237–239, 1991a.

    Article  Google Scholar 

  119. Stief CG, Holmquist F, Djamilian M, Krah H, Andersson K-E, Jonas U: Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. J Urol 148:1437–1440, 1992.

    PubMed  Google Scholar 

  120. Heaton JPW: Synthetic nitrovasodilators are effective, in vitro, in relaxing penile tissue from impotent men: the findings and their implications. Can J Physiol Pharmacol 67:78–81, 1989.

    PubMed  Google Scholar 

  121. Talley JD, Crawley IS: Transdermal nitrate, penile erection and spousal headache. Ann Int Med 103:804, 1985.

    PubMed  Google Scholar 

  122. Owen JA, Saunders F, Harris C, Fenemore J, Reid K, Surridge D, Condra M, Morales A: Topical nitroglycerin: a potential treatment for impotence. J Urol 141:546–548, 1989.

    PubMed  Google Scholar 

  123. Claes H, Baert L: Transcutaneous nitroglycerin therapy in the treatment of impotence. Urol Int 44:309–312, 1989.

    Article  PubMed  Google Scholar 

  124. Meyhoff HH, Rosenkilde P, Bødker A: Non-invasive management of impotence with transcutaneous nitroglycerin. Br J Urol 69:88–90, 1992.

    PubMed  Google Scholar 

  125. Sønksen J, Biering Sørensen F: Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured. Paraplegia 30:554–557, 1992.

    PubMed  Google Scholar 

  126. Weston AH, Abbott A: New class of antihypertensive acts by opening K+ channels. Trends Pharmacol Sci 8:283–284, 1987.

    Article  Google Scholar 

  127. Edwards G, Weston AH: Potassium channel openers and vascular smooth muscle relaxation. Pharmacol Ther 48:237–258, 1990.

    Article  PubMed  Google Scholar 

  128. Andersson K-E: Clinical pharmacology of potassium channel openers. Pharmacol Toxicol, 70:244–254, 1992.

    PubMed  Google Scholar 

  129. Longman SD, Hamilton TC: Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 12:73–148, 1992.

    Article  PubMed  Google Scholar 

  130. Holmquist F, Andersson K-E, Fovaeus M, Hedlund H: K+-channel openers for relaxation of isolated penile erectile tissue from rabbit. J Urol 144:146–151, 1990a. Holmquist F, Andersson K-E, Hedlund H: Effects of pinacidil on isolated human corpus cavernosum penis. Acta Physiol Scand 138:463–469, 1990b.

    PubMed  Google Scholar 

  131. Giraldi A, Wagner G: Effect of pinacidil upon penile erectile tissue, in vitro and in vivo, Pharmacol Toxicol 67:235–238, 1990.

    PubMed  Google Scholar 

  132. Hellstrom WJG, Wang R, Kadowitz PJ, Domer FR: Potassium channel agonists cause penile erection in cats. Int J Impotence Res 4:35–43, 1992.

    Google Scholar 

  133. McCall JM, Aiken JW, Chidester CG, DuCharme DW, Wendling MG: Pyrimidine and triazine 3-oxide sulfates: a new family of vasodilators. J Med Chem 26:1791–1793, 1983.

    Article  PubMed  Google Scholar 

  134. Cavallini G: Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutanous erection facilitation for organic impotence. J Urol 146:50–53, 1991.

    PubMed  Google Scholar 

  135. Clark JT, Smith ER, Davidson JM: Enhancement of sexual motivation in male rats by yohimbine. Science 225:847–848, 1984.

    Article  PubMed  Google Scholar 

  136. Smith ER, Lee RL, Schnur SL, Davidson JM: Alpha 2-adrenoceptor antagonists and male sexual behavior: I. mating behavior. Physiol Behav 41:7–14, 1987a.

    Article  PubMed  Google Scholar 

  137. Smith ER, Lee RL, Schnur SL, Davidson JM: Alpha 2-adrenoceptor antagonists and male sexual behavior: II. erectile and ejaculatory reflexes. Physiol Behav 41:15–19, 1987b.

    Article  PubMed  Google Scholar 

  138. Goldberg MR, Robertson D: Yohimbine: a pharmacological probe for study of the α2 adrenoceptor. Pharmacol Rev 35:143–180, 1983.

    PubMed  Google Scholar 

  139. Danjou P, Alexandre L, Warot D, Lacomblez L, Puech AJ: Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 26:733–739, 1988.

    PubMed  Google Scholar 

  140. Jacobsen FM: Fluoxetin-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 53:119–122, 1992.

    PubMed  Google Scholar 

  141. Charney DS, Heninger GR: Alpha2-adrenergic and opiate receptor blockade. Arch Gen Psychiatry 43:1037–1041, 1986.

    PubMed  Google Scholar 

  142. Morales A, Condra M, Owen JA, Surridge DH, Fenemore J, Harris C: Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 137:1168–1172, 1987.

    PubMed  Google Scholar 

  143. Reid K, Morales A, Harris C, Surridge DH, Condra M, Owen J: Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet i:421–423, 1987.

    Article  Google Scholar 

  144. Riley AJ, Goodman RE, Kellett JM, Orr R: Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual and Marital Therapy 4:17–26, 1989.

    Google Scholar 

  145. Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha MG: Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 141:1360–1363, 1989.

    PubMed  Google Scholar 

  146. Turchi P, Canale D, Ducci M, Nannipieri E, Serafini MF, Menchini Fabris GF: The transdermal route in the treatment of male sexual impotence: preliminary data on the use of yohimbine. Int J Impotence Res 4:45–50, 1992.

    Google Scholar 

  147. Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DHC, Morales A: The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 32:577–582, 1987.

    Article  PubMed  Google Scholar 

  148. Galitzky J, Rivière D, Tran MA, Montastruc JL, Berlan M: Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol 39:447–451, 1990.

    Article  PubMed  Google Scholar 

  149. Charney DS, Heninger GR, Sternberg DE: Assessment of alpha2adrenergic autoregulator function in humans: effects of oral yohimbine. Life Sci 30:2033–2041, 1982.

    Article  PubMed  Google Scholar 

  150. Charney DS, Heninger GR, Redmond Jr DE: Yohimbine induced anxiety and increased noradrenergic fuction in humans: effects of diazepam and clonidine. Life Sci 33:19–29, 1983.

    Article  PubMed  Google Scholar 

  151. Price LH, Charney DS, Heninger GR: Three cases of manic symptoms following yohimbine administration. Am J Psychiatr 141:1267–1268, 1984.

    PubMed  Google Scholar 

  152. Meyerson BJ, Terenius L: Beta-endorphin and male sexual behavior. Eur J Pharmacol 42: 191–192, 1977.

    Article  PubMed  Google Scholar 

  153. Pellegrini-Qurantotti B, Borda M, Paglietti E, Biggio G, Gessa G: Inhibition of copulatory behavior in male rat by D-Ala-Met-enkephalinamide. Life Sci 23:673–678, 1978.

    Article  Google Scholar 

  154. Gessa GL, Paglietti E, Pellegrini-Quarantotti B: Induction of copulatory behavior in sexually inactive rats by naloxone. Science 204:203–205, 1979.

    Article  PubMed  Google Scholar 

  155. Parr D: Sexual aspects of drug abuse in narcotic addicts. Br J Addict 71:261–268, 1976.

    Article  Google Scholar 

  156. Crowley TJ, Simpson A: Methadone dose and human sexual behavior. Int J Addict 13: 285–295, 1978.

    PubMed  Google Scholar 

  157. Fabbri A, Janini EA, Gnessi L, Moretti C, Ulisse S, Franzese A, Lazzari R, Fraioli F, Frajese G, Isidori A: Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinol 14:103–111, 1989.

    Article  Google Scholar 

  158. Goldstein A, Hansteen RW: Evidence against involvement of endorphine in sexual arousal and orgasm in man. Arch Gen Psychiatr 34:1179–1180, 1977.

    PubMed  Google Scholar 

  159. Goldstein JA: Erectile function and naltrexone. Ann Intern Med 105:799, 1986.

    PubMed  Google Scholar 

  160. Bitran D, Hull EM: Pharmacological analysis of male rat sexual behavior. Neurosci Biobehav Rev 11:365–389, 1987.

    Article  PubMed  Google Scholar 

  161. Foreman MM, Hall JL: Effects of D2 dopaminergic receptor stimulation on male rat sexual behavior. J Neural Transm 68:153–170, 1987.

    Article  PubMed  Google Scholar 

  162. Mogilnika E, Klimek V: Drugs affecting dopamine neurons and yawning behaviour. Pharmacol Biochem Behav 31:303–305, 1977.

    Article  Google Scholar 

  163. Benassi-Benelli A, Ferrari F, Pellegrini-Quarantotti B: Penile erection induced by apomorphine and N-n-propylnorapomorphine in rats. Arch Int Psychodyn Ther 242:241–247, 1979.

    Google Scholar 

  164. Lal S, Ackman D, Thavundayil JX, Kiely M, Etienne P: Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuro-Psychopharmacol Biol Psychiat 8:695–699, 1984.

    Article  Google Scholar 

  165. Lal S, Laryea E, Thavundayil JX, Vasavan Nair NP, Negrete J, Ackman D, Blundell P, Gardiner RJ: Apomorphine-induced penile tumescence in impotent patients-preliminary findings. Prog Neuro-Psychopharmacol Biol Psychiat 11:235–242, 1987.

    Article  Google Scholar 

  166. Lal S, Tesfaye Y, Thavundayil JX, Thompson TR, Kiely ME, Nair NPV, Grassino A, Dubrovsky B: Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuro-Psychopharmacol Biol Psychiat 13:329–339, 1989.

    Article  Google Scholar 

  167. Vogel HP, Schiffer R: Hypersexuality—a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiat 16:107–110, 1983.

    Google Scholar 

  168. Zarrindast M-R, Shokravi S, Samini M: Opposite influences of dopaminergic receptor subtypes on penile erection. Gen Pharmacol 23:671–675, 1992.

    PubMed  Google Scholar 

  169. Pomerantz SM: Quinelorane (LY 163502), a D2 dopamine receptor agonist, acts centrally to faciliate penile erections of male rhesus monkeys. Pharmacol Biochem Behav 39:123–128, 1991.

    Article  PubMed  Google Scholar 

  170. Julien E, Over R: Male sexual arousal with repeated exposure to erotic stimuli Arch Sexual Behavior 13:211–221, 1984.

    Article  Google Scholar 

  171. Segraves RT, Bari M, Segraves K, Spirnak P: Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol 145:1174–1175, 1991.

    PubMed  Google Scholar 

  172. Diederichs W, Stief CG, Lue TF, Tanagho EA: Norepinephrine involvement in penile detumescence. J Urol 143:1264–1266, 1990.

    PubMed  Google Scholar 

  173. Winter CC, McDowell G: Experience with 105 patients with priapism: update review of all aspects. J Urol 140:980–983, 1988.

    PubMed  Google Scholar 

  174. Lin JS-N, YU-P-C, Yang MCM, Kuo J-S: Detumescent effect of clonidine on penile erection. Int J Impotence Res 1:201–210, 1989.

    Google Scholar 

  175. Zorgniotti AW: Editorial comment. J Urol 136:110, 1986.

    Google Scholar 

  176. Levin RM, Wein AJ: Adrenergic alpha-receptors outnumber beta-receptors in human penile corpus cavernosum. Invest Urol 18:225–226, 1980.

    PubMed  Google Scholar 

  177. Dhabuwala CB, Ramakrishna VR, Anderson GF: Beta adrenergic receptors in human cavernous tissue. J Urol 133:721–723, 1985.

    PubMed  Google Scholar 

  178. Molina L, Bejany D, Lynne CM, Politano VA: Diluted epinephrine solution for the treatment of priapism. J Urol 141:1127–1128, 1989.

    PubMed  Google Scholar 

  179. van Driel MF, Mooibroek JJ, Mensink HJA: Treatment of priapism by injection of adrenaline into the corpora cavernosa penis. Scand J Urol Nephrol 25:251–254, 1991.

    PubMed  Google Scholar 

  180. Zappala SM, Howard PJ, Hopkins TB, Blute RD: Management of intraoperative penile erections with diluted epinephrine solution. Urology 40:76–77, 1992.

    Article  PubMed  Google Scholar 

  181. Dittrich A, Albrecht K, Bar-Moshe O, Vandendris M: Treatment of pharmacological priapism with phenylephrine. J Urol 146:323–324, 1991.

    PubMed  Google Scholar 

  182. Levine FJ, Saenz de Tejada I, Payton TR, Goldstein I: Recurrent prolonged erections and priapism as a sequela of priapism: pathophysiology and management. J Urol 145:77664–767, 1991.

    Google Scholar 

  183. Zaimis E: Vasopressor drugs and catecholamines. Anesthesiology 29:732–762, 1968.

    Article  PubMed  Google Scholar 

  184. Stief CG, Gilbert P, Wetterauer U, Bähren W, Thon W, Altwein JE: Metaraminol—ein Antidot bei SKAT-bedingter prolongierter Erektion. Urologe 25:164–165, 1986.

    PubMed  Google Scholar 

  185. Block T, Sturm W, Ernst G, Staehler G, Schmiedt E: Metaraminol in der Therapie verschiedener Priapismusformen. Urologe 27:225–229, 1988

    PubMed  Google Scholar 

  186. Watters GR, Keogh EJ, Carati CJ, Earle CM, Wisniewski ZS, Tulloch AGS, Lord DJ: Prologed erections following intracorporeal injection of mediacations to overcome impotence. Br J Urol 62:173–175, 1988.

    PubMed  Google Scholar 

  187. Porst H, van Ahlen H: Pharmakon-induzierte Priapismen-ein Erfahrungsberich über 101 Falle. Urologe 28:84–87, 1989.

    PubMed  Google Scholar 

  188. Goldberg LI, Rajfer EI: Dopamine receptors: applications in clinical cardiology. Circulation 72:245–248, 1985.

    PubMed  Google Scholar 

  189. Lue TF, Hellstrom WJG, McAninch JW, Tanagho EA: Priapism: a refined approach to diagnosis and treatment. J Urol 136:104–108, 1986.

    PubMed  Google Scholar 

  190. Shantha TR, Finnerty DP, Rodriquez AP: Treatment of persistent penile erection and priapism using terbutaline. J Urol 141:1427–1429, 1989.

    PubMed  Google Scholar 

  191. Bondil P: Letter to the Editor. J Urol 144:1483, 1989.

    Google Scholar 

  192. Nieder RM: Ketamine treatment of priapism. J Am Med Ass 221:195, 1972.

    Article  Google Scholar 

  193. Ravindran RS, Dryden GE, Somerville GM: Treatment of priapism with ketamine and physostigmine. Anesth Analg 61:705–707, 1982.

    PubMed  Google Scholar 

  194. McMahon CG: A comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin PGE1 and a combination of all three agents in the management of impotence. Int J Impotence Res 3:113–121, 1991.

    Google Scholar 

  195. Allen RP, Engel RM, Smoley JK, Brendler CB: Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1. J Urol 148:1181–1183, 1992.

    PubMed  Google Scholar 

  196. Steers WD, Selby Jr JB: Use of methylene blue and selective embolization of the pudendal artery for high flow priapism refractory to medical and surgical treatments. J Urol 146: 1361–1363, 1991.

    PubMed  Google Scholar 

  197. Freygang H, Djamilian M, Thon WF, Stief CG, Jonas U: A new therapeutic concept for long-lasting iatrogenic priapism: a case report. J Urol 148:878–879, 1992.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, University Hospital of Lund, S-221 85, Lund, Sweden

    Karl-Erik Andersson M.D., Ph.D.

Authors
  1. Karl-Erik Andersson M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andersson, KE. Pharmacology of erection: Agents which initiate and terminate erection. Sex Disabil 12, 53–79 (1994). https://doi.org/10.1007/BF02547898

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02547898

Key Words

Search

Navigation